Menu
Menu
Investment Partner
Anthony is responsible for our global investment strategy. He has a wealth of experience overseeing cross-border biopharma deals. He started his career as a strategy consultant at Monitor Deloitte, where he was responsible for M&A strategy for the world’s leading MNC’s. Prior to joining ZhongMei Capital, Anthony also held leadership positions in business development and strategy at Gilead Sciences and Jazz Pharmaceuticals. His experience working for and with many of the US’s leading biopharmaceutical companies provides managerial oversight to our current portfolio companies.
Anthony holds an MBA from Columbia Business School, and a BS in chemistry from the University of California at Davis.
Clinical Partner
Stephen J. Peroutka, MD, PhD is an advisor at ZhongMei Capital, where he focuses on evaluating and providing strategic medical input for the US clinical development for our portfolio companies. Dr. Peroutka was most recently Vice
President and Global Therapeutic Area Head for Neuroscience at PPD, one of the world’s largest CRO’s, where he provided medical strategy advice on global clinical trials in neuroscience. Prior to PPD, Dr. Peroutka held clinical leadership roles at Zogenix, Johnson and Johnson, and Genentech.
Dr. Peroutka holds M.D and Ph.D (in
neuropharmacology) degrees from the Johns Hopkins University School of
Medicine, and an A.B from Cornell University.
Venture Partner
Quan Vu is a venture partner at ZhongMei Capital, where he focuses on post-investment management, fundraising, and partnership strategy in the United States. Quan was most recently the Chief Financial Officer/Chief Business Officer of Ocugen, a publicly traded gene therapy company. He has also held leadership positions at 180 Life Sciences, Opiant Pharmaceuticals, Impax, and Amgen. Quan started his career as a healthcare investment banker at bulge bracket firms, including Goldman Sachs and Morgan Stanley.
Quan holds an MS in Legal Studies from Cornell Law School, and a B.A. in Economics from UCLA
Anthony is responsible for HuntBest’s global strategy and partnerships. He has a wealth of experience overseeing cross-border biopharma deals. He started his career as a strategy consultant at Monitor Deloitte, where he was responsible for developing pipeline strategy for the world’s leading MNC’s. Prior to joining HuntBest, Anthony also held leadership positions in business development and strategy at Gilead Sciences and Jazz Pharmaceuticals. His experience working for and with many of the US’s leading biopharmaceutical companies provides valuable insight to HuntBest’s current and future portfolio companies.
Anthony holds an MBA from Columbia Business School, and a BS in chemistry from the University of California at Davis.
Ethan is responsible for HuntBest’s investments in novel technologies and modalities, with a particular lean towards SiRNA platforms. He has a long and successful track record as an executive in the healthcare CMC space, having served as the Vice President and Associate General Manager of Asymchem, a leading CDMO in China prior to joining HuntBest. While at Asymchem, he oversaw the clinical development and manufacturing of many of China’s leading pharmaceutical compounds. He currently also serves as a Council Member of the TongXieYi RNA Therapeutics Committee, where he is involved in the bleeding edge of new RNA therapeutics research.
Ethan holds a PhD in chemistry from the Chinese Academy of Sciences and has been published in journals such as JACS, ACIE, and ORPD during his time as an academic researchers.
Kevin founded HuntBest with the intention of providing both funding and expertise to undercapitalized and undiscovered entrepreneurs in China. His global vision for HuntBest has attracted a myriad of top-tier LP’s, corporate partnerships, and high-growth portfolio companies. Prior to founding HuntBest, Kevin held a leadership position at PrimaVera Capital, where he was responsible for deploying overseas investments and managing global partnerships. Prior to HuntBest, Kevin was an investment banker at Goldman Sachs, where he covered M&A transactions in the renewables space.
Kevin holds a PhD in chemistry from the Chinese Academy of Sciences, a post-doctoral from the University of Wisconsin, and an MBA from the Rotman School of Management.
Wenjun is responsible for managing the HuntBest’s domestic healthcare portfolio. He has a deep expertise in clinical operations and start-up investing, and serves as a board advisor to many of the companies he has invested in. Prior to HuntBest, Wenjun was an investment manager at Teda Venture Capital, where he oversaw venture investments into promising Chinese healthcare companies. Prior to Teda Venture Capital, Wenjun was a R&D project director as Asymchem, as leading Chinese CDMO, where he was responsible for ensuring timely and efficient clinical operations for his biopharmaceutical clients.
Wenjun holdTsinghuas a PhD in chemistry from Nankai University, and a post-doctoral at Georgia State University and University.
